Search results
Author(s):
Jeffrey Weitz
Added:
2 years ago
Dr Jeffrey Weitz (Thrombosis & Atherosclerosis Research Institute, Ontario, CA) presents the results of the Axiomatic-TKR Study, a phase II dose-ranging study that aims to examine the effect of Milvexian versus Enoxaparin in the treatment of venous thromboembolism in patients undergoing total-knee replacement surgery.The study met its efficacy criteria, where the rate of thromboembolism was…
View more
Author(s):
Raymond B Fohtung
,
Michael W Rich
Added:
3 years ago
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, with an overall prevalence of approximately 1 % in the general population.1 An estimated 2.3 million adults in the US have AF, and this number is projected to increase to 5.6 million by 2050.1 The most clinically important complication from AF lies in the risk for cardiac thrombus formation and systemic embolism…
View more
Author(s):
Duk-Woo Park
Added:
1 year ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827).
The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR.
Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less…
View more
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
4 months ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more
Nils Kucher
Job title: Professor of Angiology / Director University Clinic of Angiology
Author
Author(s):
Sonika Malik
,
Anju Bhardwaj
,
Matthew Eisen
,
et al
Added:
3 years ago
Pulmonary embolism (PE) is a common and serious manifestation of venous thromboembolism (VTE) and is an important cause of morbidity and mortality in the US. The incidence is estimated to be 50 per 100,000 but increases to 500 per 100,000 in the elderly.1 There is a wide spectrum of clinical severity with mortality estimates of 1–2 % in stable individuals and up to 30 % in patients presenting…
View more
Christian Ruff
Author
Author(s):
Mirvat Alasnag
Added:
1 year ago
In this short and practice focused review, Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SA) highlights some of the late-breaking clinical trials presented atACC.22from an interventionalist perspective.
Trials covered in detail include:
00:58: SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
01:46: GHATI: Improving STEMI Management Internationally: Two…
View more
Author(s):
Naima Maqsood
,
Jeff Healey
Added:
4 months ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of…
View more